A new tool dubbed Insight Engine by Expert.ai is intended to process vast amounts of data related to the life sciences.
Users can plan future studies by using the historical and ongoing clinical trial data that is made available by Insight Engine. Moreover, a database of published articles is automatically consulted for the assessment of patent claims.
Expert.ai asserts that deeper analysis of clinical trial data will be possible with its Insight Engine.
By mining biomedical data and information, Insight Engine can expedite the drug discovery process by informing users about possible new drug discoveries.
When conducting clinical trials, researchers mine vast amounts of data from numerous sources to gain valuable insights.
According to Christophe Aubry, head of life sciences and health care at Expert.ai, “the complexity of biomedical data, combined with the dynamic and fast-paced nature of the Pharma and Life Sciences domain itself demands very practical and advanced tools to effectively stay up to date with the latest knowledge in real-time and at scale.”
The global clinical trials, private scientific publications, and public resources for particular treatments are the “triangle of data sources” from which knowledge may be readily synthesized using “the expert.ai Insight Engine for Life Sciences,” according to the speaker.
Drug research and clinical trials are frequently labor-intensive processes that can take ten or fifteen years to finish.
With its potential to increase production and efficiency, artificial intelligence (AI) is upending a number of industries, including healthcare.
According to a research from the MIT Sloan School, AI might increase worker productivity by up to 40%.
According to research and analysis firm GlobalData, in 2024 27% of companies in a range of industries reported a high rate of AI integration within their operations.
Over the course of the upcoming year, GlobalData anticipates that this percentage will rise.
It projects that the entire worldwide AI market will be valued more than $909 billion by 2030.
